Antoinette Hiebeler-Hasner
Direktor/Vorstandsmitglied bei MEDIGENE AG
Ursprung des Netzwerks ersten Grades von Antoinette Hiebeler-Hasner
Einheit | Art der Einheit | Industrie | |
---|---|---|---|
15
| Public Company | Biotechnology | 15 |
Vistra GmbH & Co. KG Wirtschaftsprüfungsgesellschaft
Vistra GmbH & Co. KG Wirtschaftsprüfungsgesellschaft Other Consumer ServicesConsumer Services Part of Vistra Group Ltd., Vistra GmbH & Co. KG Wirtschaftsprüfungsgesellschaft is a company based in Cologne, Germany. The German company specializes in helping investments grow and succeed internationally, providing investment and transaction services. The company has experts in fund services and private equity who can navigate local regulations and nuances in over 45 jurisdictions throughout the funds lifecycle. The company was founded in 2009 and has Kerstin Bors, Joachim Buchau, and Peter Lenz as CEOs. Vistra GmbH & Co. KG Wirtschaftsprüfungsgesellschaft was acquired by Vistra SA on April 03, 2017.
4
| Subsidiary | Other Consumer Services | 4 |
Grob Aircraft SE
Grob Aircraft SE Aerospace & DefenseElectronic Technology Part of H3 AEROSPACE GmbH & Co. KG, Grob Aircraft SE is a German company that manufactures and sells aircrafts. The company is based in Tussenhausen-Mattsies, Germany. The company was founded in 1971. The CEO is André Hiebeler.
4
| Subsidiary | Aerospace & Defense | 4 |
Ventuz Technology AG
Ventuz Technology AG Packaged SoftwareTechnology Services Ventuz Technology AG provides software solutions for authoring and displaying real-time interactive, data-driven graphics to markets with high-end requirements. The private company is based in Hamburg, Germany. The German company's products, Ventuz Designer, Director, and Runtime, are based on DirectX and Microsoft .NET and are compatible with MS Windows systems only. The company also offers a Ventuz and Substance integration for both Substance products: Substance Designer and Substance Painter. The company was founded in 2004. The CEO is Ralf Stanke.
1
| Private Company | Packaged Software | 1 |
Unternehmensgrafik - zweiten Grades
Beziehungen zu mehreren Unternehmen
Unternehmensverbindungen über das persönliche Netzwerk von Antoinette Hiebeler-Hasner
Unternehmen | Sektor | Verknüpfte Personen | Hauptposition |
---|---|---|---|
Centocor, Inc.
Centocor, Inc. Medical SpecialtiesHealth Technology Centocor, Inc. manufactures healthcare products. Its products include avakine & reopro. The company was founded in 1979 by Hubert J. P. Schoemaker & Michael A. Wall and is headquartered in Horsham, PA. | Medical Specialties | Corporate Officer/Principal | |
ELI LILLY AND COMPANY | Pharmaceuticals: Major | Corporate Officer/Principal | |
MERCK KGAA | Pharmaceuticals: Major | Corporate Officer/Principal | |
4SC AG | Biotechnology | Investor Relations Contact | |
Aeras Global TB Vaccine Foundation
Aeras Global TB Vaccine Foundation Miscellaneous Commercial ServicesCommercial Services Aeras Global TB Vaccine Foundation is a non-profit organization, which engages in the development of tuberculosis vaccines in partnership with other biotech, pharmaceutical, and academic organizations. Its product pipeline includes AdS Ag85A, MTBCAV, VPM 1002, and RUTI. The company is headquartered in Rockville, MD. | Miscellaneous Commercial Services | Director/Board Member | |
AC IMMUNE SA | Pharmaceuticals: Major | Investor Relations Contact | |
SOCIÉTÉ GÉNÉRALE | Regional Banks | Corporate Officer/Principal | |
BARCLAYS PLC | Investment Banks/Brokers | Director/Board Member | |
UCB | Pharmaceuticals: Major | Corporate Officer/Principal | |
LINDT | Food: Specialty/Candy | Treasurer | |
IsoTis SA
IsoTis SA BiotechnologyHealth Technology IsoTis SA develops biomedical products. Its product include proprietary natural and synthetic bone graft substitutes and other related medical devices. These devices are used to enhance the repair and regeneration of bone in spinal and trauma surgery, joint replacements and dental applications. IsoTis' products are primarily used spinal fusion, trauma, joint revision, bone void filling and iliac crest backfills procedures. The company is headquartered in Lausanne, Switzerland. | Biotechnology | Chief Tech/Sci/R&D Officer | |
3i Deutschland Gesellschaft für Industriebeteiligungen mbH
3i Deutschland Gesellschaft für Industriebeteiligungen mbH Investment ManagersFinance 3i Deutschland Gesellschaft für Industriebeteiligungen mbH (3i Deutschland) is the German private equity subsidiary of 3i Group Plc (LSE: III) in Great Britain. Established in Frankfurt in 1984, the firm invests in small and medium-sized German companies at all stages of development, from start-ups to established businesses. In addition to the Frankfurt office, 3i Deutschland has offices in Munich and Stuttgart. They drive their investment focus and decisions from their Frankfurt and Munich offices, and the team collaborates with Swiss colleagues in Zurich and 3i's network across Europe, Asia and the U.S. to invest in a wide range of industry sectors. | Investment Managers | Private Equity Investor | |
Imperial College London | College/University | Undergraduate Degree | |
Bryan, Garnier & Co Ltd.
Bryan, Garnier & Co Ltd. Investment Banks/BrokersFinance Bryan, Garnier & Co Ltd. is a European, full-service growth-focused independent investment bank for technology, healthcare, consumer, and business services companies. The private company is based in London, UK, and has a global presence of subsidiaries in several regions. The British company is well-positioned in a capex intensive industry that is increasingly dynamic both in capital raising and M & A, driven by the 4th Industrial Revolution. Bryan Garnier is the world's leading independent full-service investment bank for European healthcare and technology-led companies and their investors. The company is focused on new disruptive technologies and alternative production models in a variety of domains geared towards fighting climate change and environmental degradation. The consumer sector is transformed across its segments by the way digital natives relate to brands, products, and the environment. The company was founded in 1996 by Olivier Marie Paul Garnier de Falletans. | Investment Banks/Brokers | Analyst-Equity | |
MediGene, Inc.
MediGene, Inc. Pharmaceuticals: MajorHealth Technology MediGene, Inc. develops herpes simplex virus technologies for the treatment of tumors and for gene delivery. The company was founded by Ram Bhatt and Frank Tufaro and is headquartered in San Diego, CA. | Pharmaceuticals: Major | Chief Executive Officer Chief Executive Officer | |
Chiron Behring & Co.
Chiron Behring & Co. Medical DistributorsDistribution Services Part of Novartis AG, Chiron Behring & Co. is a German company that supplies and develops new vaccine products for adults and children. The company is based in Marburg, Germany. Chiron Behring was acquired by Chiron Corp. from Hoechst AG on April 01, 1998 for $111.90 million. | Medical Distributors | Chief Executive Officer | |
Monash University
Monash University Other Consumer ServicesConsumer Services Monash University operates as a public research university. It specializes in higher education, global engagement, postgraduate courses, undergraduate study, and PhD research. The company was founded on March 1961 and is headquartered in Clayton, Australia. | College/University | Doctorate Degree | |
BASILEA PHARMACEUTICA AG | Pharmaceuticals: Major | President Chief Executive Officer | |
Massachusetts Institute of Technology | College/University | Graduate Degree Masters Business Admin | |
University of Wisconsin | College/University | Doctorate Degree | |
CELLECTIS S.A. | Pharmaceuticals: Major | Director/Board Member | |
University of Amsterdam | College/University | Doctorate Degree | |
Allergan Ltd.
Allergan Ltd. Pharmaceuticals: MajorHealth Technology Allergan Ltd. provides eye care and specialty pharmaceutical products. It develops pharmaceutical products used for treatment of eye and skin care medications and neurological disorders. The firm develops products for glaucoma, dry eye, blepharospasm, cervical, dystonia, hemi-facial spasm, post-stroke spasticity and cerebral palsy. The company was founded in 1977 and is headquartered in Marlow, the United Kingdom. | Pharmaceuticals: Major | Corporate Officer/Principal | |
NEOVACS | Pharmaceuticals: Major | Director/Board Member | |
University of Regensburg | College/University | Doctorate Degree | |
DMS IMAGING | Biotechnology | Chairman | |
Sensimed SA
Sensimed SA Medical SpecialtiesHealth Technology Sensimed SA develops non-invasive soft contact lens-based solutions. It offers solutions to monitor fluctuations in intraocular pressure continuously. The company was founded by Matteo Leonardi and Sacha Cerboni in 2003 and is headquartered in Lausanne, Switzerland. | Medical Specialties | Chief Tech/Sci/R&D Officer | |
EryDel SpA
EryDel SpA Medical SpecialtiesHealth Technology EryDel SpA offers medical research. It develops drugs and diagnostics delivered through human red blood cells via a medical device technology. The company was founded by Luigia Rossi and Mauro Magnani in 2007 and is headquartered in Bresso, Italy. | Medical Specialties | Chief Tech/Sci/R&D Officer | |
PHARNEXT SCA | Biotechnology | Chief Tech/Sci/R&D Officer | |
H3 AEROSPACE GmbH & Co. KG
H3 AEROSPACE GmbH & Co. KG Aerospace & DefenseElectronic Technology H3 AEROSPACE GmbH & Co. KG engages in the acquisition, manufacture, marketing, leasing and sale of airplanes. The company was founded by Antoinette Hiebeler-Hasner in 2006 and is headquartered in Tussenhausen-Mattsies, Germany. | Aerospace & Defense | Chief Executive Officer | |
Novartis Pharma AG
Novartis Pharma AG Pharmaceuticals: MajorHealth Technology Novartis Pharma AG engages in the research in as well as the production and distribution of pharmaceutical, chemical, medical, and biotechnological products. It also provides related services. The company was founded on October 25, 1989 and is headquartered in Basel, Switzerland. | Pharmaceuticals: Major | Corporate Officer/Principal | |
Zeus Capital Ltd. (Broker) | Investment Banks/Brokers | Analyst-Equity | |
Helmholtz-Zentrum für Infektionsforschung GmbH
Helmholtz-Zentrum für Infektionsforschung GmbH BiotechnologyHealth Technology Helmholtz-Zentrum für Infektionsforschung GmbH provides bio-medical research and development services. The firm engages in research projects focused on infection biology and its clinical application and practical implementation. It also specializes in the examination of pathogens that are either medically relevant or that can be used as models for the research of infections. Its research topics encompass bacterial and viral pathogens, immune response, and anti-infectives. The company was founded in 1965 and is headquartered in Braunschweig, Germany. | Biotechnology | Director/Board Member | |
Immodulon Therapeutics Ltd.
Immodulon Therapeutics Ltd. BiotechnologyHealth Technology Part of Lifexx SA, Immodulon Therapeutics Ltd. is a late-stage clinical biotechnology company based in Uxbridge, UK. Immodulon is developing a highly differentiated cancer immunotherapy approach that primes the patient’s own innate immune system with the aim to significantly enhance the efficacy of a broad range of anti-cancer therapies, including chemotherapy and checkpoint inhibitors. The British company is developing imm-101, a heat-killed mycobacterium obuense, as a broad-spectrum immunomodulatory agent with the potential to treat a range of difficult-to-treat tumors including those considered to be immunologically “ cold, ” such as pancreatic cancer. Immodulon's imm-101 based immunotherapy complements other cancer therapies, including immune checkpoint inhibitors and chemotherapy. The company is focused on developing safe and effective immunotherapy treatments. The company was founded in 2007 by Charles Akle, John L. Stanford. Gertjan Bartlema has been the CEO of the company since 2022. | Biotechnology | Director/Board Member | |
Themis Bioscience GmbH
Themis Bioscience GmbH Pharmaceuticals: MajorHealth Technology Themis Bioscience GmbH operates as a biotechnology company, which engages in the development of prophylactic vaccinations from preclinical to early clinical phase. The firm focuses on the prevention of tropical infectious diseases. Its proprietary Themaxyn technology platform, in-licensed from Paris-based Institute Pasteur, forms the basis of all of the company's vaccine candidates. The company was founded by Erich Tauber in 2009 and is headquartered in Vienna, Austria. | Pharmaceuticals: Major | Chairman | |
European Research Council
European Research Council Investment Trusts/Mutual FundsMiscellaneous The European Research Council is an organization that provides grants for research projects. The organization is based in Brussels, Belgium. As a grantee, individuals are required to submit scientific and financial reports for assessment by ERC Scientific Officers. The organization emphasizes the importance of research ethics and compliance with legislation, disciplinary norms, and protection of research subjects. The responsibility for ethics lies with the individuals conducting the research, while the formal accountability lies with the signatory of the Grant Agreement, the Host Institution. | Investment Trusts/Mutual Funds | Corporate Officer/Principal | |
Serono International SA | Chief Tech/Sci/R&D Officer | ||
Deutsche Forschungsgemeinschaft | College/University | Corporate Officer/Principal | |
MSD Wellcome Trust Hilleman Laboratories Pvt Ltd.
MSD Wellcome Trust Hilleman Laboratories Pvt Ltd. BiotechnologyHealth Technology MSD Wellcome Trust Hilleman Laboratories Pvt Ltd. develops and researches vaccines. The joint venture company is based in Gurgaon, India. The company was founded in 2009. Raman Rao has been the CEO of the Indian company since 2020. | Biotechnology | Chairman | |
DERMIRA, INC. | Pharmaceuticals: Major | Corporate Officer/Principal | |
Medigene Immunotherapies GmbH
Medigene Immunotherapies GmbH Pharmaceuticals: MajorHealth Technology Part of MediGene AG, Medigene Immunotherapies GmbH develops immunotherapy to treat cancer. The company is based in Planegg, Germany. The German company was founded in 2013 by Thomas Blankenstein, Dolores J. Schendel. The CEO is Axel-Sven Malkomes. Medigene Immunotherapies was acquired by MediGene AG on January 27, 2014 for $13.05 million. | Pharmaceuticals: Major | Chief Executive Officer Chief Executive Officer | |
German Cancer Aid | Corporate Officer/Principal | ||
CONNECT BIOPHARMA HOLDINGS LIMITED | Pharmaceuticals: Major | Corporate Officer/Principal |
Statistik
International
Vereinigte Staaten | 11 |
Deutschland | 11 |
Schweiz | 9 |
Vereinigtes Königreich | 8 |
Frankreich | 5 |
Sektoral
Health Technology | 30 |
Finance | 8 |
Consumer Services | 7 |
Commercial Services | 2 |
Consumer Non-Durables | 2 |
Operativ
Director/Board Member | 46 |
Chief Executive Officer | 38 |
Corporate Officer/Principal | 34 |
Director of Finance/CFO | 15 |
Independent Dir/Board Member | 14 |
Am stärksten vernetzte Beziehungen
Insiders | |
---|---|
David Lemus | 22 |
Thomas Taapken | 16 |
Wolfgang Hans Josef Hanrieder | 16 |
Frank Mathias | 15 |
Stefan Giesler | 12 |
René Goedkoop | 12 |
Gerd Zettlmeissl | 11 |
Dolores Schendel | 9 |
Olav Zilian | 9 |
Gary Waanders | 8 |
Selwyn Ho | 8 |
Axel-Sven Malkomes | 7 |
Ronald Scott | 7 |
Anthony Man | 3 |
Anna Niedl | 2 |
- Börse
- Insiders
- Antoinette Hiebeler-Hasner
- Unternehmensverbindungen